The typical flow cytometric approach for the assessment of T-lymphoblastic leukemia/lymphoma MRD includes the identification of neoplastic cells with decreased expression of CD45, expression of CD34, absence of expression of CD4 and CD8 or dual expression of these markers, overexpression of CD7, or aberrant expression of one or more myeloid or B cell markers identified at the time of diagnosis. This evidence concerns the gene CD34 and lymphoma.